{"id":"https://openalex.org/W2138016988","doi":null,"title":"Angiotensin receptor blockers - advantages of the new sartans.","display_name":"Angiotensin receptor blockers - advantages of the new sartans.","publication_year":2013,"publication_date":"2013-07-01","ids":{"openalex":"https://openalex.org/W2138016988","mag":"2138016988","pmid":"https://pubmed.ncbi.nlm.nih.gov/24772750"},"language":"en","primary_location":{"id":"pmid:24772750","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24772750","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of the Association of Physicians of India","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048457833","display_name":"Zia Al Sabbah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zia Al Sabbah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037221652","display_name":"Aijaz Mansoor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aijaz Mansoor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5053721496","display_name":"Upendra Kaul","orcid":"https://orcid.org/0000-0002-4798-7098","observed_orcids":["https://orcid.org/0000-0002-4798-7098","https://orcid.org/0009-0009-5241-9325"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Upendra Kaul","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8717,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.75994622,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"61","issue":"7","first_page":"464","last_page":"70"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.04610000178217888,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9980000257492065},{"id":"https://openalex.org/keywords/telmisartan","display_name":"telmisartan","score":0.9909999966621399},{"id":"https://openalex.org/keywords/olmesartan-medoxomil","display_name":"olmesartan medoxomil","score":0.9879999756813049},{"id":"https://openalex.org/keywords/renin-angiotensin-system","display_name":"renin-angiotensin system","score":0.9480000138282776},{"id":"https://openalex.org/keywords/angiotensin-ii","display_name":"angiotensin II","score":0.8420000076293945},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.5410000085830688},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.7749999761581421},{"id":"https://openalex.org/keywords/endothelial-function","display_name":"endothelial function","score":0.8399999737739563},{"id":"https://openalex.org/keywords/albuminuria","display_name":"albuminuria","score":0.9330000281333923},{"id":"https://openalex.org/keywords/ontarget-trial","display_name":"ONTARGET trial","score":0.6919999718666077},{"id":"https://openalex.org/keywords/transcend-trial","display_name":"TRANSCEND trial","score":0.9679999947547913},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.7559999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9566501379013062},{"id":"https://openalex.org/C2779766728","wikidata":"https://www.wikidata.org/wiki/Q421156","display_name":"Olmesartan","level":3,"score":0.887627124786377},{"id":"https://openalex.org/C2779716603","wikidata":"https://www.wikidata.org/wiki/Q733186","display_name":"Telmisartan","level":3,"score":0.8337558507919312},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.5481857657432556},{"id":"https://openalex.org/C104849204","wikidata":"https://www.wikidata.org/wiki/Q24778533","display_name":"Angiotensin receptor","level":4,"score":0.5299385786056519},{"id":"https://openalex.org/C2776174234","wikidata":"https://www.wikidata.org/wiki/Q974792","display_name":"Albuminuria","level":3,"score":0.5152974128723145},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.509074866771698},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4618033766746521},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.45043492317199707},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.44822579622268677},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4481543302536011},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.446969211101532},{"id":"https://openalex.org/C123915805","wikidata":"https://www.wikidata.org/wiki/Q15332826","display_name":"Angiotensin II receptor type 1","level":4,"score":0.4372677206993103},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4255523085594177},{"id":"https://openalex.org/C2910553456","wikidata":"https://www.wikidata.org/wiki/Q285044","display_name":"Angiotensin Receptor Blockers","level":4,"score":0.41192659735679626},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.24278146028518677}],"mesh":[{"descriptor_ui":"D000068557","descriptor_name":"Olmesartan Medoxomil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077333","descriptor_name":"Telmisartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000419","descriptor_name":"Albuminuria","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001565","descriptor_name":"Benzoates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010069","descriptor_name":"Oxadiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047228","descriptor_name":"Angiotensin II Type 1 Receptor Blockers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:24772750","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24772750","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of the Association of Physicians of India","raw_type":"Journal Article"},{"id":"mag:2138016988","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24772750","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W72197365","https://openalex.org/W75251984","https://openalex.org/W108690756","https://openalex.org/W1966000112","https://openalex.org/W1974814786","https://openalex.org/W1976167638","https://openalex.org/W1977080874","https://openalex.org/W1984061204","https://openalex.org/W1994696430","https://openalex.org/W2001079133","https://openalex.org/W2018824917","https://openalex.org/W2028439883","https://openalex.org/W2029160123","https://openalex.org/W2031335602","https://openalex.org/W2038286610","https://openalex.org/W2039665384","https://openalex.org/W2042282631","https://openalex.org/W2052017394","https://openalex.org/W2056976690","https://openalex.org/W2061528318","https://openalex.org/W2078775644","https://openalex.org/W2080742733","https://openalex.org/W2088521596","https://openalex.org/W2105473163","https://openalex.org/W2120434113","https://openalex.org/W2126045082","https://openalex.org/W2129697991","https://openalex.org/W2136948246","https://openalex.org/W2140319788","https://openalex.org/W2143046445","https://openalex.org/W2144528818","https://openalex.org/W2152043519","https://openalex.org/W2152798629","https://openalex.org/W2160643831","https://openalex.org/W2330539553","https://openalex.org/W2602157665"],"related_works":["https://openalex.org/W2130630180","https://openalex.org/W2415106727","https://openalex.org/W7099609688","https://openalex.org/W7062869307","https://openalex.org/W2907840079","https://openalex.org/W766861400","https://openalex.org/W4379796458","https://openalex.org/W2042821753","https://openalex.org/W2565294201","https://openalex.org/W2109169392"],"abstract_inverted_index":{"Advantages":[0],"of":[1,14,43,49,68,93,116],"the":[2,41,66,69,91,94,114],"new":[3],"angiotensin":[4],"receptor":[5],"blockers":[6],"(ARBs)":[7],"include":[8],"once":[9],"daily":[10],"dosing,":[11],"an":[12],"absence":[13],"significant":[15],"adverse":[16],"reactions,":[17],"well":[18],"tolerated":[19],"side":[20],"effect":[21],"profile":[22],"and":[23,54,80,96,118],"cost":[24],"effectiveness.":[25],"A":[26],"growing":[27],"realization":[28],"is":[29,100],"their":[30],"beneficial":[31],"pleotropic":[32],"effects.":[33],"Antihypertensive":[34],"agents":[35],"are":[36],"widely":[37],"used":[38],"to":[39],"reduce":[40],"risk":[42,88],"cardiovascular":[44,87,103],"events":[45],"partly":[46],"beyond":[47],"that":[48,108],"blood":[50],"pressure-lowering.":[51],"The":[52],"RAAS,":[53],"its":[55],"primary":[56],"mediator":[57],"Ang":[58],"II,":[59],"also":[60],"have":[61,106],"a":[62],"direct":[63],"influence":[64],"on":[65,74,90],"progression":[67,115],"atherosclerotic":[70],"process":[71],"via":[72],"effects":[73],"endothelial":[75],"function,":[76],"inflammation,":[77],"fibrinolytic":[78],"balance,":[79],"plaque":[81],"stability.":[82],"For":[83],"patients":[84],"at":[85],"high":[86],"based":[89],"results":[92],"ONTARGET":[95],"TRANSCEND":[97],"studies,":[98],"telmisartan":[99],"indicated":[101],"for":[102],"prevention.":[104],"Studies":[105],"shown":[107],"olmesartan":[109],"medoxomil":[110],"treatment":[111],"may":[112],"slow":[113],"atherosclerosis":[117],"postpone":[119],"albuminuria":[120],"thereby":[121],"potentially":[122],"improving":[123],"CV":[124],"outcomes.":[125]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}